Assessment of pharmacokinetic–pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae
- 1 January 2005
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 51 (1) , 45-49
- https://doi.org/10.1016/j.diagmicrobio.2004.08.019
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Clinical pharmacodynamics of quinolonesInfectious Disease Clinics of North America, 2003
- Resistance to Levofloxacin and Failure of Treatment of Pneumococcal PneumoniaNew England Journal of Medicine, 2002
- Fluoroquinolone PharmacodynamicsClinical Infectious Diseases, 2001
- Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract InfectionsAntimicrobial Agents and Chemotherapy, 2001
- Risk Factors for Acquisition of Levofloxacin-Resistant Streptococcus pneumoniae: A Case-Control StudyClinical Infectious Diseases, 2001
- Multiple-Dose Pharmacokinetics and Tolerability of Gemifloxacin Administered Orally to Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2001
- Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC BreakpointAntimicrobial Agents and Chemotherapy, 2001
- Activities and Postantibiotic Effects of Gemifloxacin Compared to Those of 11 Other Agents against Haemophilus influenzae and Moraxella catarrhalisAntimicrobial Agents and Chemotherapy, 2000
- Antipneumococcal Activities of Gemifloxacin Compared to Those of Nine Other AgentsAntimicrobial Agents and Chemotherapy, 2000
- Decreased Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in CanadaNew England Journal of Medicine, 1999